Table 3.
Travel characteristics of sub-groups of immunocompromised travelers
| HIV | Solid-organ transplant (N = 61) | TNF inhibitors (N = 73) | ||
|---|---|---|---|---|
| CD4 ≥ 500 cells/mm3 (N = 71) | CD4 < 500 cells/mm3 (N = 39) | |||
| Top destinations | Kenya (8%) | South Africa (15%) | India (15%) | India (18%) |
| Ghana (7%) | Ghana (10%) | China (10%) | Thailand (10%) | |
| Guinea (7%) | India (8%) | Italy (8%) | Kenya (7%) | |
| South Africa (7%) | Peru (8%) | Greece (7%) | Cambodia (7%) | |
| Senegal (8%) | ||||
| Zambia (8%) | ||||
| Travel to region with low human development (UNHDI classification)* | 33 (46%) | 20 (51%) | 5 (8%) | 23 (32%) |
| Purpose of travel† | ||||
| Leisure | 36 (51%) | 18 (46%) | 31 (51%) | 41 (56%) |
| Business | 14 (20%) | 6 (15%) | 12 (20%) | 17 (23%) |
| VFR | 16 (23%) | 16 (41%) | 11 (18%) | 2 (3%) |
| Non-medical service work | 2 (3%) | 0 | 1 (2%) | 2 (3%) |
| Missionary work | 1 (1%) | 0 | 6 (10%) | 1 (1%) |
| Adventuring | 3 (4%) | 1 (3%) | 0 | 2 (3%) |
| Days before departure visited travel clinic (median, range) | 21 (0–257) | 22 (4–98) | 22 (0–252) | 25 (0–353) |
*
United Nations Human Development Index (UNHDI).
†
Visiting friends and relatives (VFR).